MedTrace Logo

Sotagliflozin as Prevention of Anthracycline-Related Cardiotoxicity

NCT07572175 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-05-07

No results posted yet for this study

Summary

This project aims to determine the benefits of the dual SGLT1/2 inhibition as prophylactic treatment to prevent anthracycline-related cardiotoxicity.

Conditions

Interventions

DRUG

Sotagliflozin

Sotagliflozin 400mg starting prior to the first scheduled anthracycline infusion

DRUG

Placebo

Placebo starting prior to the first scheduled anthracycline infusion

Sponsors & Collaborators

Principal Investigators

  • Carlos G Santos-Gallego, MD · Icahn School of Medicine at Mount Sinai

  • Santos-Gallego, MD · Icahn School of Medicine at Mount Sinai

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-31
Primary Completion
2029-06-30
Completion
2029-10-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07572175 on ClinicalTrials.gov